Sublocade vs. Vivitrol: What to Know About Each

Choosing between Sublocade and Vivitrol can feel a little like being told to pick between two monthly shots that somehow live in completely different universes. They may both show up once a month, but they do very different jobs. One is a buprenorphine-based medication that helps calm withdrawal and cravings. The other is a naltrexone-based medication that blocks opioid effects after detox. Same calendar vibe, very different chemistry.

That matters because opioid use disorder treatment is not one-size-fits-all. Some people need a medication that makes early recovery physically easier. Others want a non-opioid option once they have already completed detox. Some are balancing work, parenting, transportation, stigma, or a history of relapse right after leaving treatment. In real life, those details are not footnotes. They are the plot.

This guide breaks down Sublocade vs. Vivitrol in plain English: how each medication works, who may be a better candidate, how starting treatment differs, what side effects and safety issues matter, and what the research says when the two approaches are compared. Think of it as the practical version of the conversation many people wish they had before standing in a clinic room wondering why two monthly injections are definitely not the same thing.

Sublocade vs. Vivitrol at a Glance

How Sublocade Works

Sublocade is a once-monthly injectable form of buprenorphine, which is a partial opioid agonist. That phrase sounds opioid agonist. That phrase sounds very pharmacology-textbook, but the real-life takeaway is simpler: it attaches to opioid receptors strongly enough to reduce withdrawal symptoms and cravings, but it does not act the same way as full opioids like heroin, fentanyl, or oxycodone.

In practical terms, Sublocade is often appealing for people who need stability. It can help smooth out the daily roller coaster of chasing a dose, missing a dose, or feeling mentally preoccupied with medication timing. Because it is a monthly injection, it may also reduce the burden of taking a tablet or film every day. For some people, that feels freeing. For others, it simply feels like fewer moving parts, which is not glamorous, but it is useful.

There is one important catch: Sublocade is not meant to be the first step. Patients generally need to start on a buprenorphine-containing medication first and be stabilized before transitioning to the injection. The standard Sublocade schedule begins with 300 mg monthly for the first two months, followed by 100 mg monthly as maintenance, though some people may remain on 300 mg if the clinical benefit outweighs the risk.

How Vivitrol Works

Vivitrol is a once-monthly injection of extended-release naltrexone. Unlike buprenorphine, naltrexone is not an opioid. It is an opioid antagonist, which means it blocks opioid receptors instead of activating them. If opioids are the unwanted party guests, Vivitrol is the bouncer at the door.

That blocking action is exactly why Vivitrol can be an effective tool for relapse prevention. It is also why starting it is trickier. If someone still has opioids in their system or is physiologically dependent, naltrexone can trigger precipitated withdrawal. Translation: the body does not take the surprise well. Because of that, Vivitrol is typically used after opioid detoxification, not during the early phase when cravings and withdrawal are still front and center.

Vivitrol also has one distinction that makes it especially interesting in some cases: it is approved not only for opioid dependence relapse prevention after detox, but also for alcohol dependence. So if someone has both opioid use disorder and alcohol use disorder, Vivitrol may enter the conversation for reasons that go beyond opioids alone.

The Biggest Difference: Starting Treatment

If you remember only one thing from this article, make it this: the real-world difference between Sublocade and Vivitrol often starts before the first injection ever happens.

Starting Sublocade

To begin Sublocade, a patient usually starts with transmucosal buprenorphine first, such as a tablet, film, or similar formulation. Once that dose is adjusted and the patient is clinically stable, the monthly injection can replace daily dosing. So yes, there is still an initiation process, but it is generally more compatible with people who are currently opioid-dependent and trying to avoid relapse during the fragile early window of treatment.

Starting Vivitrol

To begin Vivitrol, the patient needs to be opioid-free first. Standard guidance typically recommends at least 7 to 10 days without opioids, and some patients coming from longer-acting opioids, methadone, or buprenorphine may need a longer transition. This is the reason many people struggle to start Vivitrol even when they want to. The medication itself may be a solid fit, but the bridge required to get there can be rough.

That difference matters so much that it shapes the research. In head-to-head studies, Vivitrol often looks less favorable in intention-to-treat comparisons partly because fewer people make it through the detox-and-initiation hurdle. Once patients are actually started on treatment, the gap between the two options can narrow.

Which Medication May Be Better for Different People?

There is no universal winner in the Sublocade vs. Vivitrol discussion. A better question is: better for whom, and at what stage?

Sublocade may make more sense if:

The person is currently opioid-dependent, has active cravings, or has struggled to stay opioid-free long enough to start an antagonist medication. It can also be attractive for people who do well on buprenorphine but want a monthly injection instead of daily medication. Some patients like the privacy of not carrying medication, while others like the consistency of a clinician-administered dose that cannot be accidentally skipped on a rough Tuesday.

Vivitrol may make more sense if:

The person has already completed detox, strongly prefers a non-opioid treatment, or also needs treatment support for alcohol use disorder. It may also be appealing for people who want no opioid activity at all in their treatment plan, including some individuals leaving controlled environments such as residential treatment or incarceration where detox has already occurred.

In other words, Sublocade often fits people who need help getting stable, while Vivitrol often fits people who are already through detox and focused on staying that way. That is not a rule carved into marble, but it is a useful clinical shortcut.

What the Research Says

The research on buprenorphine vs. extended-release naltrexone tells a story that is more nuanced than a simple “this one wins” headline.

One of the most discussed trials, the X:BOT study, found that in all randomized patients, buprenorphine performed modestly better on relapse outcomes. But here is the crucial detail: much of that difference came from the fact that many more patients assigned to extended-release naltrexone failed to start it in the first place because of the detox requirement. Among people who successfully initiated medication, outcomes were much more similar.

Another randomized study in newly detoxified patients found that extended-release naltrexone was noninferior to buprenorphine-naloxone for short-term abstinence outcomes. That does not erase the initiation challenge, but it does show why Vivitrol remains an important option. If a patient can successfully get onto it, it may work quite well.

There is also a newer wrinkle: rapid initiation protocols for extended-release naltrexone are being studied and may shorten the time to first injection in some settings. That is promising, though it usually requires more intensive monitoring and staffing. So the story is evolving, but the main point still stands: Vivitrol’s biggest limitation is often getting to dose one, not necessarily what happens after dose one.

Safety, Side Effects, and Everyday Practical Issues

Sublocade side effects and considerations

Common Sublocade side effects include constipation, headache, nausea, vomiting, fatigue, injection-site itching or pain, and increased liver enzymes. Because it contains buprenorphine, it still carries opioid-related cautions. It is also a Schedule III controlled substance, and it is distributed through a restricted REMS program, which means access depends on certified healthcare settings and pharmacies.

One practical point people sometimes overlook: Sublocade is still part of the buprenorphine family. That can be a strength, because buprenorphine has a strong evidence base for reducing cravings and helping people stay in treatment. But it also means it is not the right fit for someone specifically seeking a totally opioid-free medication approach.

Vivitrol side effects and considerations

Common Vivitrol issues include injection-site reactions, nausea, insomnia, upper respiratory symptoms, toothache, and liver-related lab abnormalities. The labeling also emphasizes the risk of reduced opioid tolerance. That matters because if someone misses doses, stops treatment, or tries to override the opioid blockade, the risk of overdose can rise sharply.

Vivitrol also complicates pain management. Because it blocks opioid receptors, opioid pain medications may not work the usual way. For a patient who might need surgery or complex pain treatment, that is not a small footnote. It is a real planning issue.

Access and Convenience: The Part People Usually Learn the Hard Way

Both medications are monthly injections, but convenience is not just about how often the needle appears.

Sublocade can be easier to start for someone with ongoing opioid dependence, but it still requires a prior buprenorphine phase and must be administered through qualified settings because of its REMS requirements. Vivitrol can be prescribed and administered more broadly, and it is not a controlled substance, but the detox barrier can make access feel more theoretical than practical for some patients.

This is why treatment planning should not stop at “Which medication sounds better?” A better set of questions is:

Can the patient safely complete detox? Have they done well on buprenorphine before? Do they also have alcohol use disorder? Is daily medication a burden? Is relapse most likely during early withdrawal, or later after detox? Those answers usually point more clearly toward the right medication than brand names alone.

Final Takeaway

In the Sublocade vs. Vivitrol debate, the smartest answer is usually not “Which one is stronger?” It is “Which one fits this person’s stage of recovery, medical history, and real life?”

Sublocade is often the more practical choice for people who need help controlling cravings and withdrawal and who benefit from the proven buprenorphine pathway without taking a daily medication. Vivitrol is often a compelling choice for people who have already completed detox, want a non-opioid option, or may also benefit from treatment that addresses alcohol use disorder.

The monthly shot is not the story. The timing, mechanism, and fit are the story. And in addiction medicine, fit is not a luxury feature. It is often the difference between a treatment plan that lives on paper and one that actually works in the wild.

Real-World Experiences and Recovery Scenarios

The most useful way to understand Sublocade vs. Vivitrol is sometimes through the kind of situations people actually face.

Imagine a person leaving detox who has relapsed several times during the first week after discharge. They are motivated, sincere, and absolutely tired of starting over. In that kind of case, Sublocade may feel attractive because the person does not have to win the “stay opioid-free long enough for Vivitrol” obstacle course before getting meaningful medication support. They start with buprenorphine, stabilize, and then move to the monthly injection. For someone whose danger zone is the first chaotic stretch after treatment, that sequence can feel less like a theory and more like a lifeline.

Now picture someone else who has already completed detox in a residential program and says, very clearly, “I do not want to be on an opioid medication, even a treatment medication.” That preference matters. If the person is fully informed and clinically appropriate for it, Vivitrol may line up better with their goals. The monthly injection gives them a non-opioid option, and for some patients that psychological fit is a big deal. Recovery is hard enough without feeling like your treatment plan is fighting your values every morning.

There are also patients who have done well on sublingual buprenorphine but hate the daily routine. Some worry about forgetting doses. Some feel self-conscious carrying medication. Some simply want fewer opportunities for treatment to become the center of the day. For those patients, Sublocade can feel like moving from a daily chore chart to autopilot. Not magic. Not effortless. But easier.

Then there is the person with both opioid use disorder and alcohol use disorder. That is where Vivitrol can become especially interesting. Instead of addressing only one substance problem, it may help support recovery in both areas. That does not make it automatically better, but it does make it strategically valuable in the right case.

What these experiences have in common is simple: the “best” medication is usually the one a person can start, stick with, and build a life around. In addiction treatment, the perfect plan on paper is rarely as powerful as the workable plan in real life.